A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Novo Nordisk’s NVO amycretin, which targets GLP-1 and amylin in one molecule, generated 24% placebo-adjusted weight loss in a ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists often partially inform or misinform consumers.

For people with diabetes, the use of GLP-1 RAs is associated with reduced risk for certain disorders and conditions.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...